Posts by Cindy
-
-
-
-
-
-
-
-
-
ADDEX ADX10061 RECEIVES £1.2 MILLION FUNDING FOR MANUFACTURE AND INVESTIGATOR LED CLINICAL STUDIES AS PART OF THE TOOLS FOR HUMAN DRUG AND BRAIN RESEARCH (THUNDR2) INITIATIVE FROM THE WELLCOME TRUST
Geneva, Switzerland, 20 September 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that it has joined the Human Drug and Brain Research (THuNDR2) initiative. THuNDR2 is a collaboration between leading UK neuroscientists, drug development experts and Addex which has been established to study the role of the D1 receptor, the main dopamine receptor, in human brain function with a grant of £1.2 million from the Wellcome Trust. The D1 receptor is believed to play a vital role in attention, concentration, as well as addiction to tobacco and other drugs. The THuNDR2 initiative is led by Prof David Nutt from Imperial College London and includes the universities of Cambridge, Bristol, Exeter, Oxford and Kings College London.
-
-
-
2018
30.04.2018 – Addex Therapeutics Ltd
Addex Reports 2017 Full Year Results and Provides Corporate Update
-
Robust cash position of CHF45 million following capital raise in Q1 2018
-
Major global licensing agreement with Indivior in addiction
Geneva, Switzerland, 30 April 2018 - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today reported its full-year results for the year ended 31 December 2017 and provided a corporate update.
"2017 saw us making significant strides towards rebuilding value for shareholders in Addex. Our concerted efforts in business development and investor relations were rewarded with an important partnership with Indivior PLC, the world's leading developer of addiction treatments, and a transformational financing, both announced during the first quarter 2018," said Tim Dyer, CEO of Addex. "These significant achievements will allow us to deliver on multiple key product development milestones in 2018, most importantly the start of registrational studies for our lead allosteric modulator, dipraglurant, in levodopa induced dyskinesia associated with Parkinson's disease."
2017 Operating Highlights
-
Continued preparing dipraglurant for the start of US registration studies
-
ADX71441 program
-
Awarded $5.3 million grant from US National Institute on Drug Abuse to support human studies in the treatment of cocaine use disorder
-
Demonstrated statistically significant effect in preclinical model of osteoarthritic pain
-
Preclinical data published on effect in alcohol use disorder
-
-
Awarded $835,000 grant from The Michael J Fox Foundation for Parkinsons Research to advance TRKB PAMs for the treatment of Parkinson's disease
Key 2017 Financial Data
CHF' thousands 2017 2016 change Income 499 411 21% R&D expenses (2,628) (2,461) 7% G&A expenses (1,106) (1,079) 3% Total operating loss (3,235) (3,129) 3% Finance result, net (45) (20) 125% Net loss for the period (3,280) (3,149) 4% Basic and diluted net loss per share 0.25 0.28 (11)% Net cash increase/(decrease) 1,219 (1,204) NA Cash and cash equivalents 2,591 1,416 83% Shareholders' equity 1,343 219 513% Financial Summary
Income in 2017 was CHF0.5 million compared to CHF0.4 million in 2016, and comprised primarily of grants from The Michel J. Fox Foundation for Parkinson's Research to cover certain clinical activities related to dipraglurant development in Parkinson's disease levodopa-induced dyskinesia and discovery activities related to our TrkB PAM program.
Research and development expenses increased by 7% to CHF2.6 million in 2017, compared to CHF2.4 million in 2016, mainly due to an increase in the number of staff and consultants deployed on the preparation of dipraglurant for registration studies in PD-LID and outsourced research costs on our Trk B PAM program. R&D expenses consist primarily of costs associated with research, preclinical and clinical testing and related staff costs. They also include depreciation of laboratory equipment and leasehold improvements, costs of materials used in research, costs associated with renting and operating facilities and equipment, as well as fees paid to consultants, patent costs and other outside service fees and overhead costs. These expenses include costs for proprietary and third party R&D.
General and administrative expenses remained stable at CHF1.1 million in 2017 compared to 2016. G&A expenses consisted primarily of staff costs, professional fees for legal, tax and strategic purposes, and overheads related to general management, human resources, finance, information technology, business development and communication functions.
The net loss for the 2017 financial year was CHF3.3 million compared to CHF3.1 million for 2016. Basic and diluted loss per share decreased to CHF0.25 for 2017, compared to CHF0.28 for 2016.
Cash and cash equivalents increased by 83% to CHF2.6 million at 31 December 2017, compared to CHF1.4 million at 31 December 2016. This increase of CHF1.2 million is primarily due to the gross proceeds of CHF3.5 million from the sale of treasury shares partially offset by the cash used in operations of CHF2.2 million
Post Year-End 2017 Balance Sheet Events
On 28 March 2018, the Company increased its share capital by issuing 13,037,577 new shares with a nominal value of CHF1 each at an issue price of CHF3.13 per share. Of these new shares, 12,917,129 were placed with investors raising CHF40.4 million of gross proceeds and the remaining 120,448 new shares were recorded as treasury shares, bringing the total outstanding issued share capital to 28,564,031. Each new share received a 7 year warrant to purchase 0.45 of a share at a price of CHF3.43.On 2 January 2018, the group signed a licencing and collaboration agreement with Indivior PLC for the global development and commercialization of ADX71441 for the treatment of addiction. An upfront payment of USD5.0 million has been received in January 2018.
At 31 March 2018, Addex had cash and cash equivalents of approximately CHF45 million.
2017 Annual Report
The 2017 annual report can be found on the investor relations page of our websiteConference Call Details
A conference call will be held today Monday, 30 April 2018 at 3:00 p.m. CET / 10:00 a.m. EDT to review the financial results. Tim Dyer, Chief Executive Officer, Roger Mills, Chief Medical officer and Robert Lütjens, Head of Discovery will deliver a brief presentation followed by a Q&A session.Joining the Conference Call:
- In the 10 minutes prior to the call start time, call the appropriate participant dial-in number.
Dial-In Numbers :
- Switzerland +41 44 580 65 22
- UK +44 20 30 09 24 70
- US +1 87 74 23 08 30
- Other countries
- Provide the operator with the conference ID: 64132152#
-
-
-
Ich habe die Aktie seit mehreren Jahren auf dem Radar und die Entwicklung mitverfolgt. Die Pipeline ist meiner Ansicht nach vielversprechend, die Finanzierung für die nächste Zeit gesichert und es stehen 3 Studien in den Startlöchern - siehe auch auf der Hompage, aktualisierte Corporate Presentation https://www.addextherapeutics.…_Addex_Corporate_Deck.pdf
Aber schliesslich muss jeder selber Entscheiden, welche Akteinkäufe, -verkäufe er tätigt. Somit möchte ich auch bitten, Aktien nur aus eigener Überzeugung und nicht aufgrund irgendwelcher Foreneinträge zu kaufen - das gilt auch für meine Wenigkeit.
-
-
-
-
-
Quelle: cash.ch (27.03.2018)
Während Titel wie Tornos und Swissquote an der Börse von Fundamentaldaten angetrieben sind, finden sich dem Tourismusimmobilien-Unternehmen Orascom (+37 Prozent) oder dem Wirkstoffentwickler Addex (+22 Prozent) unter den Top Ten Unternehmen mit fortgesetzter Turnaround-Geschichte. Dass Biotech-Startups an beiden Enden der Rangliste figurieren können, zeigen Santhera und Newron, die sich in der Drei-Monate-Betrachtung unter den "Flop Ten" befinden.
Beste und schlechteste SPI-Aktien im ersten Quartal 2018
-
*mail1*
... das wird dem Kurs sicher nicht schaden 